DV
Dividend Vision

ANIP Stock — ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP)

Updated November 16, 2026.

ANIP is a stock. Total return is -76.1% over the past 25.3 years, 984.4 points behind SPY at 908.3%.

ANI Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets branded and generic pharmaceutical products, including injectables, softgel capsules, oral solids, and specialty products like ILUVIEN and YUTIQ for ophthalmic use. The company does not currently maintain a regular distribution schedule. ANI Pharmaceuticals appeals to equity investors seeking exposure to the pharmaceutical sector rather than income-focused investors.

ANIP performance versus SPY

Total return is -76.1% over the past 25.3 years, 984.4 points behind SPY at 908.3%. Over the past year its total return — price change plus distributions reinvested — is -15.5%. Its deepest 1-year drawdown was 21.6%.

WindowTotal returnCAGR
1M0.9%—
3M-4.4%—
6M-11.7%—
YTD-9.5%—
1Y-15.5%—
2Y CAGR—9.30%
3Y CAGR—11.40%
5Y CAGR—9.40%
10Y CAGR—2.20%
Since inception 2001-07-24 · 25.3 years-76.1%-5.50%

ANIP key facts

Asset type
Stock
Asset class
Equity
Inception date
07/24/2001
Distribution frequency
None
Last close
$70.89 (as of 2026-11-16)
Market cap
$1,610,545,019
Average volume
254,028
Beta
0.466
Payout ratio
0.0%
P/E ratio
14.09
Forward P/E
7.04
EPS
$5.03

How Dividend Vision calculates returns

Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ANIP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 21.6%.

Who may consider ANIP — and who may not

It is a weaker fit for investors who need monthly cash flow (ANIP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ANIP

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions

Does ANIP pay monthly?

No. ANIP does not currently distribute.

When does ANIP pay a dividend?

ANIP does not currently distribute.

How has ANIP performed?

Total return is -76.1% over the past 25.3 years, 984.4 points behind SPY at 908.3%. Over the past year its total return — price change plus distributions reinvested — is -15.5%. Its deepest 1-year drawdown was 21.6%.

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.